Guerbet's Telebrix 38 replacements approved:
This article was originally published in Clinica
Executive Summary
The French Health Ministry has officially withdrawn approval for Guerbet's Telebrix 38 X-ray contrast agent. The company decided to withdraw the products from sale last January as a "cautious move" following several reports of crystallisation (see Clinica No 638, p 14). The Ministry published approval for Guerbet's Telebrix 30 and Telebrix 35 contrast agents in the same ruling (Official journal of May 5th, 1995).
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.